
|Articles|February 10, 2023
SCOPE 2023: Biospecimen Presentation Questions & Insights
Author(s)Lisa Henderson
Hope Meely, chief clinical officer at Slope, discusses the feedback she received following her SCOPE presentation around biospecimen collection.
Advertisement
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Hope Meely, chief clinical officer at Slope, elaborates on the feedback she received surrounding her conference presentation, "The Hidden Regulatory Risk from Sample Management — What Should You Be Aware of?” This includes the agreement among attendees that the clinical trials industry needs to ensure that biospecimens are managed, especially since they are the driving factors of safety and efficacy data.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Patient Input Comes in Too Late—and What Earlier Engagement Changes
2
Recruitment in the Age of AI: Q&A with John Worden, Javara
3
What It Actually Means to Embed the Patient Voice in Trial Design
4
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
5




